IP Library › Granted Patent US 12,371,678
Granted Patent B2
US 12,371,678 · App. 17/379,563 · Granted Jul 29, 2025

Engineered transaminase polypeptides for industrial biocatalysis

Inventors: Martina Quintanar-Audelo (Edinburgh, GB); Ellen Eberhard (Fallbrook, CA); Jovana Nazor (Milpitas, CA); Derek Smith (Singapore, SG); Cuixia Wang (Singapore, SG)
Assignee: Codexis, Inc.
C12N9/1096C07D487/04C12P13/001C12P17/182C12Y206/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,678
App. No.
17/379,563
Granted
Jul 29, 2025
Kind
B2
Abstract

The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.

Claims (28)

1. An engineered polypeptide having transaminase activity comprising an amino acid sequence having at least 80% sequence identity to reference sequence of SEQ ID NO: 2 and a combination of amino acid residue differences X42A/G, X54P, and X152S/T as compared to SEQ ID NO:2 and further comprises one or more residue differences as compared to SEQ ID NO:2 selected from: X33L, X36C, X41C/R, X44Q, X51K, X76S, X122Q, X148Q, X150A, X155K, X156R, X160P, X215G, X218M, and X328I.

2. The engineered polypeptide of claim 1 , in which the amino acid sequence further comprises one or more residue differences as compared to SEQ ID NO:2, selected from: X5K, X41F/M/N, X48D/E/G/K/T, X49T, X55L, X108V, X117G, X122F, X126A, X150F, X155A/I/L/T/V, X156Q, X164P, X165N, X182T, X215H/L, X241R, X267V, X270T, X273H, and X325M.

3. The engineered polypeptide of claim 1 , further comprising

(a) an amino acid residue difference as compared to SEQ ID NO:2 selected from G36C, I41C, I41F, I41K, I41M, I41N, I41R, P48D, P48E, P48G, P48K, P48T, A51K, M122F, M122Q, Y148Q, Q155A, Q155I, Q155K, Q155T, Q155V, C215H, C215L, Y273H, L325M, and A241R; or

(b) a combination of residue differences selected from: A5K, S49T, Q155T, and W156Q; P33L, I41C, S150F, Q155K, F160P, and C215G; P33L, I41K, S150F, Q155I, F160P, and C215L; P33L, P48G, S150F, Q155T, and C215H; P33L, A109S, S150F, Q155K, W156Q, and C215H; P33L, E117G, S150F, Q155I, W156Q, and C215G; P33L, S150F, Q155I, W156Q, and C215G; P33L, S150F, Q155K, W156Q, and C215H; P33L, S150F, Q155L, W156Q, and C215H; P33L, S150F, Q155L, W156Q, C215H, and A241R; G36C, P48G, S150F, Q155I, and C215H; G36C, P48K, S150F, Q155T, and C215H; G36C, S150F, Q155I, C215H, and A241R; G36C, S150F, Q155K, C215H, and A241R; G36C, S150F, Q155T, and A241R; G36C, S150F, Q155V, and C215H; I41C, S49T, S150F, Q155I, F160P, C215G, and I267V; I41C, S49T, S150F, Q155K, W156Q, C215G and I267V; I41C, 1108V, S150F, and Q155K; I41C, I108V, S150F, Q155K, W156Q, C215G, and I267V; I41C, I108V, S150F, Q155T, W156Q, and C215G; I41C, E117G, S150F, Q155K, and F160P; 141C, E117G, S150F, Q155K, and C215L; I41C, E117G, S150F, Q155L, and C215L; I41C, S150F, Q155I, and C215G; I41C, S150F, Q155I, and C215L; I41C, S150F, Q155K, W156Q, C215G, and I267V; I41C, S150F, Q155K, and C215L; I41C, S150F, Q155K, and C215G; I41C, S150F, Q155L, F160P, C215G, and I267V; I41C, S150F, Q155T, W156Q, F160P, and C215L; I41C, S150F, Q155T, W156Q, and C215L; I41F, M122Q, S150F, Q155V, W156Q, and C215G; I41F, S150F, Q155L, W156Q, V171I, and C215G; I41F, S150F, Q155L, W156Q, V171I, C215G, and A241R; I41F, S150F, Q155I, W156Q, and C215G; I41K, P48E, S150F, Q155K, and W156Q; I41K, P48E, S150F, Q155L, and C215L; I41K, I108V, E117G, S150F, Q155K, and C215L; I41K, I108V, S150F, Q155T, and C215G; 141K, E117G, S150F, Q155L, and C215G; 141K, E117G, S150F, Q155K, C215L, and I267V; I41K, S150F, Q155K, W156Q, and C215G; I41K, S150F, Q155K, F160P, C215G, and I267V; I41K, S150F, Q155K, and C215L; I41K, S150F, and Q155T; I41K, S150F, Q155T, and F160P; I41K, S150F, Q155T, and C215G; I41K, S150F, Q155T, C215G, and I267V; I41K, S150F, Q155K, W156Q, and C215G; 141N, S150F, Q155I, and F160P; I41N, E117G, S150F, Q155T; and W156Q; I41N, S49T, S150F, Q155L, F160P, D165N, and C215L; A44Q, I108V, S150F, Q155T, and I267V; A44Q, I108V, S150F, and Q155T; A44Q, I108V, S150F, Q155T, and I267V; A44Q, S150A, and Q155T; A44Q, S150F, and Q155T; P48G, S150F, Q155L, W156Q, and C215H; P48G, S150F, and Q155T; S49T, I108V, E117G, S150F, Q155L, F160P, and C215L; S49T, 1108V, E117G, S150F, Q155K, W156Q, and C215G; S49T, I108V, E117G, S150F, Q155T, W156Q, C215G, and I267V; S49T, Q155T, and W156Q; I55L, T126A, Q155T, L218M, and A270T; F60V, S150F, Q155L, W156Q, and C215G; T68A, S150F, Q155L, W156Q, and C215G; T69S, S150F, Q155L, W156Q, and C215G; N76S, T126A, Q155T, S182T, L218M, A270T, and V328I; I108V, S150F, Q155K, and C215H; I108V, S150F, and Q155T; I108V, S150F, Q155T, and I267V; I108V, S150F, Q155V, W156Q, and F160P; E117G, and Q155T; E117G, Q155T, and W156Q; M122Q, S150F, Q155I, W156Q, C215G, and A241R; M122Q, S150F, Q155L,W156Q, V171I, C215G, and A241R; M122Q, S150F, Q155V, W156Q, V171I, C215G, and A241R; T126M, S150F, Q155L, W156Q, and C215G; P135I, F136Y, S150F, Q155L, W156Q, W192F, and C215G; F136I, S150F, Q155L, W156Q, and C215G; F136I, S150F, Q155L, W156Q, C215G, and G224I; F136I, S150F, Q155L, W156Y, C215G, S282V, and G284I; F136I, S150F, Q155L, W156Y, C215G, and G284P; F136Y, S150F, Q155L, W156Q, C215G, S282V, and G284P; S150A, Q155T, and I267V; S150F, Q155I, W156Q, F160P, C215L, and I267V; S150F, Q155I, W156Q, V171I, C215G, and A241R; S150F, Q155I, W156Q, and C215L; S150F, Q155I, F160P, and C215G; S150F, Q155I, and C215H; S150F, Q155K, and W156Q; S150F, Q155K, W156Q, and 1267V; S150F, Q155L, W156Q, G193M, and C215G; S150F, Q155L, W156Q, and C215G; S150F, Q155L, W156Q, C215G, S282V, and G284I; S150F, Q155L, W156Q, C215G, and T283S; S150F, Q155L, W156Q, C215G, and G284I; S150F, Q155L, W156Y, and C215G; S150F, Q155L, and C215H; S150F, and Q155T; S150F, Q155T, C215G, and I267V; S150F, Q155T, and I267V; S150F, Q155T, W156Q, F160P, C215L, and I267V; S150F, Q155T, W156Q, C215G, and I267V; S150F, Q155T, and W156R; S150F, Q155T, F160P, and C215G; S150F, Q155T, F160P, and C215L; S150F, Q155T, C215G, and I267V; S150F, Q155T, and I267V; Q155I, and W156S; Q155K, and W156S; Q155L, and W156S; Q155T; Q155T, and F160P; Q155T, and R164P; W156Q; Q155T, and W156S; Q155T, and R164P; Q155T, S182T, L218M, and A270T; Q155T, and C215G; Q155T, and C215L; and Q155V, and W156S.

4. The engineered polypeptide of claim 1 , wherein said engineered polypeptide is capable of converting a substrate compound (2)

to a product compound (1)

under suitable reaction conditions.

5. The engineered polypeptide of claim 4 , which is capable of converting compound (2) to compound (1) with at least 1.2 fold the activity of SEQ ID NO:2 under suitable reaction conditions.

6. The engineered polypeptide of claim 5 , in which the suitable reaction conditions comprise compound (2) loading of at least 50 g/L, 1 mM PLP, 50% DMSO (v/v), 1.5 M isopropylamine, pH 11, and 55° C.

7. The engineered polypeptide of claim 1 , in which the amino acid sequence comprises SEQ ID NO: 130.

8. The engineered polypeptide of claim 1 , in which the polypeptide is immobilized on a solid support.

9. The engineered polypeptide of claim 8 , in which the solid support is a bead or resin comprising polymethacrylate with epoxide functional groups, polymethacrylate with amino epoxide functional groups, styrene/DVB copolymer or polymethacrylate with octadecyl functional groups.

10. A process for preparing a compound of structural Formula (I):

having the indicated stereochemical configuration at the stereogenic center marked with an *; in an enantiomeric excess of at least 70% over the opposite enantiomer,

wherein

Z is OR 2 or NR 2 R 3 ;

R1 is C1-8 alkyl, aryl, heteroaryl, aryl-C1-2 alkyl, heteroaryl-C1-2 alkyl, or a 5- to 6-membered heterocyclic ring system optionally containing an additional heteroatom selected from O, S, and N, the heterocyclic ring being unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C1-4 alkoxy, and C1-4 alkyl, wherein alkyl and alkoxy are unsubstituted or substituted with one to five fluorines;

R2 and R3 are each independently hydrogen, C1-8 alkyl, aryl, or aryl-C1-2 alkyl; or

R2 and R3 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring system optionally containing an additional heteroatom selected from O, S, and N, the heterocyclic ring being unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C1-4 alkoxy, and C1-4 alkyl, wherein alkyl and alkoxy are unsubstituted or substituted with one to five fluorines; and the heterocyclic ring system being optionally fused with a 5- to 6-membered saturated or aromatic carbocyclic ring system or a 5- to 6-membered saturated or aromatic heterocyclic ring system containing one to two heteroatoms selected from O, S, and N, the fused ring system being unsubstituted or substituted with one to two substituents selected from hydroxy, amino, fluorine, C1-4 alkyl, C1-4 alkoxy, and trifluoromethyl; the process comprising the step of contacting a compound of structural Formula (II):

with an engineered polypeptide of claim 1 in the presence of an amino group donor in a suitable organic solvent under suitable reaction conditions.

11. The process of claim 10 , wherein R1 is benzyl wherein the phenyl group of benzyl is unsubstituted or substituted one to three substituents selected from the group consisting of fluorine, trifluoromethyl, and trifluoromethoxy.

12. The process of claim 10 , wherein Z is NR 2 R 3 .

13. The process of claim 12 , wherein NR 2 R 3 is a heterocycle of the structural Formula (III):

wherein R4 is hydrogen or C1-4 alkyl which is unsubstituted or substituted with one to five fluorines.

14. The engineered polypeptide of claim 1 , in which the amino acid sequence comprises one or more residue differences as compared to SEQ ID NO:2, selected from X42A/G, X54P, X150A/F, X152S/T, X155A/I/K/L/T/V, X156Q/R/S, and X215G/H/L.

15. The engineered polypeptide of claim 1 , in which the amino acid sequence comprises one or more residue differences as compared to SEQ ID NO:2, selected from X42A/G, X54P, and X152S/T.

16. The engineered polypeptide of claim 15 , in which the amino acid sequence comprises one or more residue differences as compared to SEQ ID NO:2, selected from X42G, X54P, and X152S.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (6)
Continuation 16790534 · Feb 13, 2020
Continuation 15945549 · Apr 4, 2018
Continuation 15443792 · Feb 27, 2017
Division 14768408
Provisional Application 61770814 · Feb 28, 2013
Related Publication 20210348138A1 · Nov 11, 2021
References Cited (114)
US 4518692A · Rozzell · 1985 [cited by applicant]
US 4600692A · Wood et al. · 1986 [cited by applicant]
US 4826766A · Rozzell · 1989 [cited by applicant]
US 4950606A · Stirling et al. · 1990 [cited by applicant]
US 5169780A · Stirling et al. · 1992 [cited by applicant]
US 5300437A · Stirling et al. · 1994 [cited by applicant]
US 5316943A · Kidman et al. · 1994 [cited by applicant]
US 6117679A · Stemmer · 2000 [cited by applicant]
US 6197558B1 · Fotheringham · 2001 [cited by applicant]
US 6376246B1 · Crameri et al. · 2002 [cited by applicant]
US 6537746B2 · Arnold et al. · 2003 [cited by applicant]
US 6586182B1 · Patten et al. · 2003 [cited by applicant]
US 7169592B2 · Yamada et al. · 2007 [cited by applicant]
US 7326708B2 · Cypes et al. · 2008 [cited by applicant]
US 7618799B2 · Coleman et al. · 2009 [cited by applicant]
US 8293507B2 · Savile et al. · 2012 [cited by applicant]
US 9617573B2 · Quintanar-Audelo et al. · 2017 [cited by applicant]
US 9963685B2 · Quintanar-Audelo et al. · 2018 [cited by applicant]
US 10604744B2 · Quintanar-Audelo et al. · 2020 [cited by applicant]
US 20020192786A1 · Yamada et al. · 2002 [cited by applicant]
US 20060195947A1 · Davis et al. · 2006 [cited by applicant]
US 20080213845A1 · Fotheringham et al. · 2008 [cited by applicant]
US 20080220990A1 · Fox · 2008 [cited by applicant]
US 20090312196A1 · Colbeck et al. · 2009 [cited by applicant]
US 20100285541A1 · Saville et al. · 2010 [cited by applicant]
US 20120329108A1 · Savile et al. · 2012 [cited by applicant]
WO 9522625A1 · 1995 [cited by applicant]
WO 9533836A1 · 1995 [cited by applicant]
WO 9600787A1 · 1996 [cited by applicant]
WO 970078A1 · 1997 [cited by applicant]
WO 9735966A1 · 1997 [cited by applicant]
WO 9827230A1 · 1998 [cited by applicant]
WO 200042651A1 · 2000 [cited by applicant]
WO 200175767A2 · 2001 [cited by applicant]
WO 2005005633A2 · 2005 [cited by applicant]
WO 2008127646A2 · 2008 [cited by applicant]
WO 2009008908A2 · 2009 [cited by applicant]
WO 2010099501A2 · 2010 [cited by applicant]
WO 2011005477A1 · 2011 [cited by applicant]
WO 2011017551A1 · 2011 [cited by applicant]
WO 2011159910A2 · 2011 [cited by applicant]
WO 2012024100A2 · 2012 [cited by applicant]
WO 2012024104A2 · 2012 [cited by applicant]
WO 2012177527A1 · 2012 [cited by applicant]
WO 2013036861A1 · 2014 [cited by applicant]
WO 2014133960A1 · 2014 [cited by applicant]
Devos et al., (Proteins: Structure, Function and Genetics, 2000, vol. 41: 98-107. [cited by examiner]
Whisstock et al., (Quarterly Reviews of Biophysics 2003, vol. 36 (3): 307-340. [cited by examiner]
Witkowski et al., (Biochemistry 38:11643-11650, 1999. [cited by examiner]
Kisselev L., (Structure, 2002, vol. 10: 8-9). [cited by examiner]
Altschul, S., et al., “Basic local alignment search tool,” J. Mol. Biol., 215: 403-410 (1990). [cited by applicant]
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 25(17):3389-3402 (1997). [cited by applicant]
Beaucage, S.L., et al., “Deoxynucleoside phosphoamidites—A new class of key intermediates for deoxypolynucleotide synthesis,” Tetrahedron Letters, 22(20):1859-62 (1981). [cited by applicant]
Black, M.E., et al., “Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy,” Proc Natl Acad Sci USA, 93:3525-3529 (1996). [cited by applicant]
Botstein, D., et al., “Strategies and applications of in vitro mutagenesis,” Science, 229(4719):1193-1201, 1985. [cited by applicant]
Caldwell, R.C., et al., “Mutagenic PCR,” PCR Methods Appl., 3:S136-S140 (1994). [cited by applicant]
Carey, F., “Sulfonate esters as substrates in nucleophilic substitution reactions,” Organic Chemistry, 2nd ed., pp. 328-331 [1992]. [cited by applicant]
Carter, P., “Site-directed mutagenesis,” Biochem. J., 237:1-7 (1986). [cited by applicant]
Christians, F.C., et al., “Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling,” Nat. Biotechnol., 17:259-264 (1999). [cited by applicant]
Crameri, A., et al., “Molecular evolution of an arsenate detoxification pathway by DNA shuffling,” Nat. Biotechnol., 15(5):436-438 (1997). [cited by applicant]
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution”, Nature, 391:288-291 (1998). [cited by applicant]
Crameri, A., et al., “Improved green fluorescent protein by molecular evolution using DNA shuffling, ”Nat. Biotechnol., 14(3):315-319 (1996). [cited by applicant]
Dale, S.J., et al., “Oligonucleotide-directed random mutagenesis using the phosphorothioate method,” Methods Mol. Biol., 57:369-74 (1996). [cited by applicant]
De Boer, H.A., et al., “The tac promoter: A functional hybrid derived from the trp and lac promoters,” Proc. Natl Acad. Sci. USA, 80: 21-25 (1983). [cited by applicant]
Ehrlich, S.D., “DNA cloning in Bacillus subtilis,” Proc Natl Acad Sci. USA, 75:1433 (1978). [cited by applicant]
Fasman, G.D.,CRC Practical Handbook of Biochemistry and Molecular Biology, CRC Press, Boca Raton, FL, pp. 3-70 [1989]. [cited by applicant]
Guo, Z., et al., “3′-End-Forming Signals of Yeast mRNA,” Mol. Cell. Biol., 15(11):5983-5990 [1995]. [cited by applicant]
Henikoff, S.,et al., “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci., 89:10915-10919 (1992). [cited by applicant]
Höhne, M., et al., “Efficient Asymmetric Synthesis of Chiral Amines by Combining Transaminase and Pyruvate Decarboxylase”, ChemBioChem, 9:363-365 (2008). [cited by applicant]
Hwang, B.-Y., et al., “High-throughput screening method for the identification of active and enantioselective ω-transaminases”, Enzyme and Microbial Technology, 34:429-436, 2004. [cited by applicant]
Iwasaki, A., et al., “Microbial synthesis of (R)- and (S)-3,4-dimethoxyamphetamines through stereoselective transamination,” Biotech. Lett., 25:1843-1846 [2003]. [cited by applicant]
Iwasaki, A., et al., “A novel transaminase, (R)-amine:pyruvate aminotransferase, from [cited by applicant]
Iwasaki, A., et al., “Microbial synthesis of chiral amines by (R)-specific transamination with [cited by applicant]
Koszelewski, D., et al., “Asymmetric Synthesis of Optically Pure Pharmacologically Relevant Amines Employing ω-Transaminases”, Adv. Synth. Catal., 350:2761-2766 (2008). [cited by applicant]
Koszelewski, D., et al., “Immobilization of omega-transaminases by encapsulation in a sol-gel/celite matrix,” Journal of Molecular Catalysis B: Enzymatic, 63: 39-44 (2010). [cited by applicant]
Kramer, B., et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of [cited by applicant]
Lathe, R., et al., “Plasmid and bacteriophage vectors for excision of intact inserts,” Gene, 57:193-201 (1987). [cited by applicant]
Lei, S.P, et al., “Characterization of the Erwinia carotovora pelB Gene and Its Product Pectate Lyase,” J Bacteriol. 169(9):4379-4383 (1987). [cited by applicant]
Ling, M., et al., “Approaches to DNA Mutagenesis:An Overview,” Anal. Biochem., 254:157-78 (1997). [cited by applicant]
Martin, A.R., et al., “Characterization of free and immobilized (S)-aminotransferase for acetophenone production,” Applied Microbiology and Biotechnology, 76(4): 843-851 (2007). [cited by applicant]
Mateo, C., et al., “Epoxy sepabeads: a novel epoxy support for stabilization of industrial enzymes via very intense multipoint covalent attachment,” Biotechnology Progress 18(3):629-34 (2002). [cited by applicant]
Matthes, H.W.D., et al., “Simultaneous rapid chemical synthesis of over one hundred oligonucleotides on a microscale,” EMBO J., 3(4):801-05 (1984). [cited by applicant]
Minshull, J., et al., “Protein evolution by molecular breeding,” Curr. Op. Chem. Biol., 3(3):284-290 (1999). [cited by applicant]
Needleman, S., et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453 (1970). [cited by applicant]
Pearson, W.R., “Improved tools for biological sequence comparison,” Proc. Nat'l. Acad. Sci. USA, 85:2444-2448 (1988). [cited by applicant]
Romanos, M.A., et al., “Foreign gene expression in yeast: a review,” Yeast 8:423-488 [1992]. [cited by applicant]
Savile, C.K., et al., “Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture,” Science 329(5989):305-9 (2010). [cited by applicant]
Shin, J.S., et al., “Comparison of the omega-transaminases from different microorganisms and application to production of chiral amines,” Biosci. Biotechnol. Biochem. 65:1782-1788 (2001). [cited by applicant]
Shin, J.S., et al., “Purification, characterization, and molecular cloning of a novel amine:pyruvate transaminase from Vibrio fluvialis JS17,” Appl. Microbiol. Biotechnol., 61(5-6):463-471 [2003]. [cited by applicant]
Simonen, M., et al., “Protein Secretion in [cited by applicant]
Smith, M., “In vitro mutagenesis,” Ann. Rev. Genet., 19:423-462 (1985). [cited by applicant]
Smith, T., et al., “Comparison of Biosequences,” Adv. Appl. Math, 2:482-489 (1981). [cited by applicant]
Stemmer, W., “DNA Shuffling by Random Fragmentation and Reassembly: In vitro Recombination for Molecular Evolution,” Proc. Natl. Acad. Sci. USA, 91:10747-10751 (1994). [cited by applicant]
Stemmer, W.P.C., “Rapid evolution of a protein in vitro by DNA shuffling”, Nature, 370:389-391 (1994). [cited by applicant]
Streitwieser, Jr., A., et al., Introduction to Organic Chemistry, 2nd ed., pp. 169-171 (1981). [cited by applicant]
Truppo, M.D., et al., “Development of an Improved Immobilized CAL-B for the Enzymatic Resolution of a Key Intermediate to Odanacatib,” Organic Process Research & Development, 15:1033-1035 (2011). [cited by applicant]
Van Ophem, P.W., et al., “Substrate inhibition of D-amino acid transaminase and protection by salts and by reduced nicotinamide adenine dinucleotide: isolation and initial characterization of a pyridoxo intermediate rel… [cited by applicant]
Villa-Komaroff, L., et al., “A bacterial clone synthesizing proinsulin,” Proc. Natl Acad. Sci. USA, 75:3727-3731 (1978). [cited by applicant]
Wells, J.A., et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene, 34:315-323 (1985). [cited by applicant]
Yi, S., et al., “Covalent immobilization of omega-transaminase from Vibrio fluvialis JS17 on chitosan beads,” Process Biochemistry 42(5): 895-898 (2007). [cited by applicant]
Yonaha, K., et al., “Distribution of ω-Amino Acid : Pyruvate Transaminase and Aminobutyrate : α-Ketoglutarate Transaminase in Microorganisms,” Agric. Biol. Chem., 47 (10):2257-2265 [1983]. [cited by applicant]
Yun, H., et al., “ω-Amino Acid:Pyruvate Transaminase from Alcaligenes denitrificans Y2k-2: a New Catalyst for Kinetic Resolution of β-Amino Acids and Amines ,” Appl. Environ. Microbiol., 70:2529-2534 [2004]. [cited by applicant]
Zhang, H., et al., “PolyA_DB: a database for mammalian mRNA polyadenylation,” Nucleic Acids Res. 33:D116-D120 (2005). [cited by applicant]
Zhang, J-H., et al., “Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening ,” Proc. Nat. Acad. Sci., U.S.A., 94:4504-4509 (1997). [cited by applicant]
Zhao, H., et al., “Molecular evolution by staggered extension process (StEP) in vitro recombination,” Nat. Biotechnol., 16:258-261 (1998). [cited by applicant]
GenBank Accession No. BAK39753.1 dated Feb. 16, 2012. [cited by applicant]
GenBank Accession No. ABA47738.1 dated Jan. 31, 2014. [cited by applicant]
GenBank Accession No. AEA39183.1 dated Apr. 4, 2011. [cited by applicant]
GenBank Accession No. AM902716.1 dated Feb. 27, 2015. [cited by applicant]
NCBI Accession No. YP_002257813 dated Aug. 27, 2013. [cited by applicant]
Devos, D., et al., “Practical Limits of Function Prediction,” Proteins: Structure, Function, and Genetics, 41:98-107 [2000]. [cited by applicant]
Whisstock, J.C., et al., “Prediction of protein function from protein sequence and structure,” Quarterly Reviews of Biophysics, 36(3):307-340 [2003]. [cited by applicant]
Witkowski, A., et al., “Conversion of a Beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine,” Biochemistry, 38:11643-11650 [1999]. [cited by applicant]
Kisselev, L., “Polypeptide Release Factors in Prokaryotes and Eukaryotes: Same Function, Different Structure,” Structure, 10:8-9 [2002]. [cited by applicant]